Case Study of I-SPY2 Trial
Laura Jean Esserman, M.D., MBA, Director, Carol Franc Buck Breast Care Center; Professor of Surgery and Radiology, University of California San Francisco
Screening phase II agents for neoadjuvant breast cancer, matching drugs with patients depending on biomarker subsets, including modeling longitudinal information about individual patients and using adaptive randomization.
Personalizing NSCLC Therapy: The BATTLE-2 Program
Vassiliki Papadimitrakopoulou, M.D., Professor, Department of Thoracic/Head and Neck Medical Oncology, Medical Oncology, The University of Texas MD Anderson Cancer Center
Comparing the efficacy of experimental therapies within biomarker subsets of non-small-cell lung cancer using adaptive randomization with primary endpoint 8-week disease control.
Beyond I-SPY 2 and BATTLE
Donald Berry, Ph.D., Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center
Extending the I-SPY 2 and BATTLE trial designs beyond breast and non-small-cell cancer, incorporating combinations of experimental agents and adapting therapies within as well as across patients.
BATTLE-2 and I-SPY 2: The Industry Perspective
Emmett V. Schmidt, M.D., Ph.D., Senior Principal Scientist, Clinical Research, Merck Research Laboratories - Oncology
KEYNOTE PRESENTATION:
Sandra J. Horning, M.D., Senior Vice President, Global Head, Clinical Development Hematology/Oncology, Genentech
Featured Panel
Bringing Targeted and Tailored Therapies to Patient
Moderator:
- Donald Berry, Ph.D., Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center
Panelists:
- Laura Jean Esserman, M.D., MBA, Director, Carol Franc Buck Breast Care Center; Professor of Surgery and Radiology, University of California San Francisco
- Vassiliki Papadimitrakopoulou, M.D., Professor, Department of Thoracic/Head and Neck Medical Oncology, Medical Oncology, The University of Texas MD Anderson Cancer Center
- Emmett V. Schmidt, M.D., Ph.D., Senior Principal Scientist, Clinical Research, Merck Research Laboratories - Oncology
- Sandra J. Horning, M.D., Senior Vice President, Global Head, Clinical Development Hematology/Oncology, Genentech
As part of the Molecular Med TRI-CON 2013, attendees have access to a partnering forum, 5 symposia, 18 short courses, and 12 core programs. The event attracts than 3,000 attendees and provides attendees an opportunity to interact with each other in the shared exhibit/poster hall, plenary keynotes and social functions.
Registration discounts are available until January 11, 2013. For complete event details visit: http://www.triconference.com/
To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup@healthtech.com.
Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at lscimemi@healthtech.com.
About Cambridge Healthtech Institute (www.chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
